The Medical Imaging and Technology Alliance (MITA) has expressed concern over the U.S. Centers for Medicare and Medicaid Services' (CMS) decision not to include coverage for beta-amyloid PET imaging as part of a new plan to cover Alzheimer's disease drugs.